3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
22
Phase 2
9
Phase 1/2
5
Phase 3
4
Phase EARLY_PHASE1
2
Phase NA
1
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
276
Gastrointestinal
10
Gynecologic
9
Genitourinary
9
Thoracic
4
Head & Neck
4
Dermatologic
3
Classical hematology
3
CNS
3
Sarcoma
2
Plasma cell
2
Other
2
Lymphoid
2
NET
1
Endocrine
1
Conditions
Pituitary Neoplasms
15
Neuroendocrine Tumors
15
Multiple Endocrine Neoplasia Type 1
9
Inflammation
4
Acromegaly
4
Sexual Dysfunction, Physiological
3
Pheochromocytoma
3
Obesity
3
Neoplasms
3
Gastro-enteropancreatic neuroendocrine tumor
3
Thyroid Cancer, Papillary
2
Prostatic Neoplasms
2
Pituitary Diseases
2
Paraganglioma
2
Carcinoid Tumor
2
Adrenal Gland Neoplasms
2
Zollinger-Ellison Syndrome
1
Vitamin D Deficiency
1
Serotonin Syndrome
1
Pituitary ACTH Hypersecretion
1
Pancreatic Neuroendocrine Tumors
1
Pancreatic Neoplasms
1
Pain, Postoperative
1
Pain
1
Neuroendocrine Tumour With Carcinoid Symptoms
1
Multiple Endocrine Neoplasia
1
Meningioma
1
Melanoma
1
Medulloblastoma
1
Lung Neoplasms
1
Interventions
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
gadobutrol
1
gadobenic acid
1
Neuropsychological Tests
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Breast Neoplasms
×
Endocrine
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled